Efficacy and Safety of Tabetri on Osteoarthritis

Inclusion Criteria: * Male or female 40 \~ 75 years of age * VAS (Visual Analogue Scale) over 30mm * Kellgren \& Lawrence Grade I\~II by X-ray * Subject who agrees to participate in this clinical trial by themselves and signs the Informed Consent Form (ICF) Exclusion Criteria: * Subjects who diagnosed inflammatory arthritis (rheumatoid arthritis, fibromyalgia, systemic lupus erythematosus, septic arthritis, gout) * Joint space under 2 mm by X-ray * Kellgren \& Lawrence Grade over III with osteophyte, irregularly-shaped auricular surfaces, or subchondral bone cyst by X-ray * Subjects who diagnosed cardiovascular disease, immune disease, infectious diseases, tumor diseases * Subjects having gastrointestinal diseases * Uncontrolled hypertension patients (Blood pressure ≥ 160/100mmHg) * Uncontrolled diabetes mellitus patients (fasting glucose level ≥ 180mg/dl) * Patients with TSH \<= 0.1 uIU/mL or \>= 10 uIU/mL * Subjects have attended abnormal values at AST or ALT (3 times excess at upper limit of the normal values) * Subjects have attended abnormal values at creatinine (2 times excess at upper limit of the normal values) * Pregnancy, breast-feeding, or subjects who have a plan to pregnancy within 3 months * Use of osteoarthritis treatment drugs or dietary supplements within 2 weeks prior to screening * Psychiatric disorder patient (schizophrenia, depressive disorder, drug abuse) * History of osteoarthritis treatment therapy within 2 weeks prior to screening * Have participated in another clinical trial within the 3 months prior to screening * Subjects who have hypersensitivity history about investigational product * Have difficulty to be participated in this clinical trial by investigator's decision